title: Advancing drug discovery: a pharmaceutics perspective.
abstract: Current industry perspective of how discovery is conducted seems to be fragmented and does not have a unified overall outlook of how discovery challenges are being addressed. Consequently, well-defined processes and drug-likeness criteria are being viewed as "broken" and will not maintain future R&D productivity. In this commentary, an analysis of existing practices for defining successful development candidates resulted in a 5 "must do" list to help advance Drug Discovery as presented from a Pharmaceutics perspective. The 5 "must do" list includes: what an ideal discovery team model should look like, what criteria should be considered for the desired development candidate profile, what the building blocks of the development candidate should look like, and how to assess the development risks of the candidate.
authors.affiliation: Kwong Eureka Solutions, Quebec, Canada.
authors.forename: Elizabeth
authors.initials: E
authors.lastname: Kwong
mesh_terms: D000818:Animals; D003257:Consumer Product Safety; D003299:Cooperative Behavior; D055808:Drug Discovery / Q000639:trends*; D004345:Drug Industry / Q000639:trends*; D006801:Humans; D033183:Interdisciplinary Communication; D061214:Patient Safety; D004364:Pharmaceutical Preparations / Q000737:chemistry* / Q000378:metabolism; D010599:Pharmacokinetics; D018570:Risk Assessment; D012995:Solubility; D057188:Workflow
chemical_list: D004364:Pharmaceutical Preparations
keywords: Drug Design; ADMET properties; MAD; developability risk assessment; drug-like properties; in-silico modeling; in-vitro models;target therapeutic profile (TPP); operating models in discovery; physicochemical properties; rule of five